Eledon Pharmaceuticals (ELDN) Competitors $3.15 +0.09 (+2.94%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$3.15 0.00 (-0.03%) As of 05/21/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELDN vs. AVBP, TRVI, PHAR, DAWN, DNTH, IOVA, ABUS, AKBA, ZYBT, and EOLSShould you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include ArriVent BioPharma (AVBP), Trevi Therapeutics (TRVI), Pharming Group (PHAR), Day One Biopharmaceuticals (DAWN), Dianthus Therapeutics (DNTH), Iovance Biotherapeutics (IOVA), Arbutus Biopharma (ABUS), Akebia Therapeutics (AKBA), Zhengye Biotechnology (ZYBT), and Evolus (EOLS). These companies are all part of the "pharmaceutical products" industry. Eledon Pharmaceuticals vs. ArriVent BioPharma Trevi Therapeutics Pharming Group Day One Biopharmaceuticals Dianthus Therapeutics Iovance Biotherapeutics Arbutus Biopharma Akebia Therapeutics Zhengye Biotechnology Evolus ArriVent BioPharma (NASDAQ:AVBP) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations. Which has stronger earnings & valuation, AVBP or ELDN? ArriVent BioPharma is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArriVent BioPharmaN/AN/A-$69.33M-$3.77-5.43Eledon PharmaceuticalsN/AN/A-$116.54M-$2.10-1.50 Which has more volatility and risk, AVBP or ELDN? ArriVent BioPharma has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500. Is AVBP or ELDN more profitable? ArriVent BioPharma's return on equity of -43.89% beat Eledon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ArriVent BioPharmaN/A -43.89% -29.67% Eledon Pharmaceuticals N/A -189.99%-28.17% Does the media favor AVBP or ELDN? In the previous week, ArriVent BioPharma had 1 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 18 mentions for ArriVent BioPharma and 17 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.25 beat ArriVent BioPharma's score of 0.61 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Eledon Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate AVBP or ELDN? ArriVent BioPharma currently has a consensus price target of $39.29, suggesting a potential upside of 91.92%. Eledon Pharmaceuticals has a consensus price target of $12.50, suggesting a potential upside of 296.83%. Given Eledon Pharmaceuticals' higher probable upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than ArriVent BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Eledon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer AVBP or ELDN? Eledon Pharmaceuticals received 5 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 73.68% of users gave Eledon Pharmaceuticals an outperform vote. CompanyUnderperformOutperformArriVent BioPharmaOutperform Votes23100.00% Underperform VotesNo VotesEledon PharmaceuticalsOutperform Votes2873.68% Underperform Votes1026.32% Do institutionals & insiders believe in AVBP or ELDN? 9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 12.3% of Eledon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryArriVent BioPharma and Eledon Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELDN vs. The Competition Export to ExcelMetricEledon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$188.63M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E Ratio-1.578.9226.7719.71Price / SalesN/A253.80393.17117.39Price / CashN/A65.8538.2534.62Price / Book10.506.466.794.50Net Income-$116.54M$143.98M$3.23B$248.18M7 Day Performance9.00%2.03%1.53%0.20%1 Month Performance-6.80%4.11%10.06%12.37%1 Year Performance5.35%-2.87%16.74%7.04% Eledon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELDNEledon Pharmaceuticals2.1569 of 5 stars$3.15+2.9%$12.50+296.8%+1.9%$188.63MN/A-1.5710News CoveragePositive NewsAnalyst RevisionGap UpAVBPArriVent BioPharma1.0148 of 5 stars$19.99-0.8%$39.00+95.1%+2.6%$680.56MN/A-7.7840Analyst ForecastTRVITrevi Therapeutics3.6005 of 5 stars$6.70+1.5%$17.56+162.1%+126.4%$669.28MN/A-15.2320Positive NewsAnalyst ForecastPHARPharming Group1.5265 of 5 stars$9.81-2.2%$30.00+206.0%+11.2%$667.04M$297.20M-37.71280Negative NewsGap UpDAWNDay One Biopharmaceuticals2.9027 of 5 stars$6.58+2.0%$30.57+364.6%-57.5%$666.96M$161.92M-6.3960DNTHDianthus Therapeutics1.2697 of 5 stars$20.08+2.5%$54.33+170.6%-23.7%$645.09M$6.24M-8.0380IOVAIovance Biotherapeutics4.4378 of 5 stars$1.93+10.3%$14.80+666.8%-83.0%$644.49M$212.68M-1.30500Trending NewsGap DownHigh Trading VolumeABUSArbutus Biopharma1.7283 of 5 stars$3.35+3.7%$5.50+64.2%-1.2%$641.46M$6.17M-7.7990News CoverageGap UpAKBAAkebia Therapeutics4.2246 of 5 stars$2.43-4.7%$6.63+172.6%+148.7%$636.14M$160.18M-10.56430Positive NewsGap DownHigh Trading VolumeZYBTZhengye BiotechnologyN/A$13.43+30.3%N/AN/A$633.44M$189.75M0.00278Gap DownEOLSEvolus3.5784 of 5 stars$9.98+1.8%$23.75+138.0%-27.1%$631.87M$266.27M-10.97170Gap UpHigh Trading Volume Related Companies and Tools Related Companies AVBP Competitors TRVI Competitors PHAR Competitors DAWN Competitors DNTH Competitors IOVA Competitors ABUS Competitors AKBA Competitors ZYBT Competitors EOLS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELDN) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredHow I profit during chaos…This Guy THRIVES on Chaos Wall Street legend Larry Benedict has thrived through every major market crash. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eledon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ELDN Stock Free ELDN Stock Alerts